XML 20 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 11,813 $ 33,509
Short-term bank deposits 14,858  
Notes receivable 4,373 389
Accounts receivable, net 19,589 15,163
Inventories, net 6,337 4,281
Prepaid assets 1,189 1,547
Other current assets 1,436 1,045
Total current assets: 64,786 57,221
Property and equipment, net 23,880 23,288
Intangible assets, net 273 205
Right-of-use assets 1,818 489
Land use rights, net 1,432 1,493
Deferred tax assets 5,619 4,695
Long-term certificates of deposit 24,568 23,431
Other assets, noncurrent 3,030 995
Total assets 125,406 116,539
Current liabilities:    
Accounts payable 108 355
Contract liabilities 61 39
Due to related parties 227 1,369
CVR excess closing cash payable   1,085
Accrued expenses and other current liabilities 10,615 11,935
Income tax payable 2,831 5,054
Operating lease liabilities, current 713 210
CVR derivative liability 4,961  
Total current liabilities: 19,516 20,047
Operating lease liabilities, noncurrent 885 199
Deferred government grants 928 213
CVR derivative liability, noncurrent   4,722
Warrant liability, noncurrent 5,668 12,835
Other noncurrent liabilities 7 49
Total liabilities 27,004 38,065
Commitments and Contingencies (Note 13)
Equity:    
Common stock, $0.001 par value, 400,000,000 shares authorized; 86,307,544 shares and 76,595,616 shares issued and outstanding at December 31, 2024 and 2023, respectively 86 77
Additional paid-in capital 136,185 68,179
Statutory reserve 3,098 3,098
Accumulated deficit (73,453) (85,538)
Accumulated other comprehensive loss (2,597) (1,644)
Total Gyre stockholders' equity (deficit) 63,319 (15,828)
Noncontrolling interest 35,083 29,777
Total equity 98,402 13,949
Total liabilities, convertible preferred stock, and equity 125,406 116,539
GC Biopharma Corp    
Current assets:    
Receivable from GCBP 4,961  
Long-term receivable from GCBP   4,722
GNI    
Current assets:    
Other receivables from GNI $ 230 1,287
Convertible Preferred Stock    
Current liabilities:    
Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; nil shares and 13,151 shares issued and outstanding at December 31, 2024 and 2023, respectively   $ 64,525